Media & Press2019-09-17T16:08:49-04:00

    Bexion Pharmaceuticals Presenting BXQ-350 Data at ASCO 2020

    May 13, 2020|

    For Immediate Release, Covington, KY May 13, 2020 Bexion Pharmaceuticals announced today that the following three abstracts submitted to the 2020 American Society of Clinical Oncology (ASCO) have been accepted for oral or poster presentation: Oral Presentation Tolerability and preliminary efficacy of BXQ-350 for refractory solid tumors and high-grade gliomas: First-in-human, first-in-class phase I trial. ... Read More

      Bexion Pharmaceuticals Receives Orphan Drug Designation for BXQ-350 for Malignant Glioma from FDA

      May 6, 2020|

      FOR IMMEDIATE RELEASE [Covington, KY May 6, 2020] Bexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted the company Orphan Drug Designation for its proprietary drug, BXQ-350, for the treatment of malignant glioma, including diffuse intrinsic pontine glioma (DIPG). DIPG primarily affects children, with most diagnoses occurring between 5 ... Read More

        Bexion Pharmaceuticals, Inc. to Present at the Precision Medicine World Conference (PMWC) 2020

        January 15, 2020|

        FOR IMMEDIATE RELEASE [Covington, KY~ January 15, 2020] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 in the Immunotherapy Showcase of the PMWC 2020 conference, ... Read More

        All Press